CJC-1295 + Ipamorelin with DAC vs. No DAC: Kylo Peptides Clarifies Labeling Across Its Research Catalog
Kylo Peptides clarifies CJC-1295 + Ipamorelin labeling so researchers can tell CJC-1295 with DAC from the no-DAC form, Mod GRF 1-29, in its catalog.
Sheridan, WY, October 07, 2026 --(PR.com)-- Kylo Peptides updated its CJC-1295 + Ipamorelin (https://kylopeptides.com/product/cjc-1295-ipamorelin-no-dac/) listing to state that it contains CJC-1295 without DAC, known as Mod GRF 1-29. The 10 mg lyophilized research blend now carries "No DAC" in its title.
"CJC-1295" covers two different molecules. The DAC form carries an albumin-binding group that extends its half-life to days in published studies. Mod GRF 1-29 omits that group.
Freedom Diagnostics, an ISO/IEC 17025-accredited lab, confirmed the blend's identity by LC-MS at 99.62% purity on Aug. 22, 2026. The certificate is in Kylo's public COA library.
Why CJC-1295 Labeling Requires Precision
The name "CJC-1295" appears in research literature and supplier catalogs for two related compounds: CJC-1295 with DAC and CJC-1295 without DAC, often called Mod GRF 1-29. Published studies describe the two forms with different chemical structures and very different half-lives.
Independent testing lab KMD Analytical notes that vendors sell the no-DAC compound under several names and spellings. Researchers reviewing a specification, paper, COA, or vial should not treat the terms as interchangeable.
Combination products need the same clarity. A CJC-1295 + Ipamorelin listing has to name both compounds and state which CJC-1295 form it carries.
Understanding the Two CJC-1295 Research Forms
Both CJC-1295 research forms are built on modified GRF(1-29), a 29-amino-acid analog of the first 29 residues of growth hormone-releasing hormone (GHRH). They differ by one added group at the end of the chain, which changes albumin binding and persistence.
CJC-1295 With DAC
DAC stands for Drug Affinity Complex, a lysine carrying a maleimidopropionamide group at the end of a tetrasubstituted GRF(1-29). Published studies have described it as binding to serum albumin.
A 2005 rat study detected the compound in plasma beyond 72 hours, and a trial in healthy adults estimated its half-life at 5.8 to 8.1 days.
CJC-1295 Without DAC / Mod GRF 1-29
CJC-1295 No DAC is the same tetrasubstituted GRF(1-29) amide with no DAC attached, often called Mod GRF 1-29 in research papers. Four amino-acid substitutions, at positions 2, 8, 15, and 27, resist breakdown by the enzyme DPP-IV. Without the albumin-binding group, it lacks the extended half-life reported for the DAC form.
Why the Names Should Not Be Used Interchangeably
Similar names make it easy to mix up a paper, a catalog listing, and a vial. A result for one form may not carry over to the other, so exact identification keeps each comparison on one molecule.
Where Kylo's CJC-1295 + Ipamorelin Product Fits
Kylo's catalog includes CJC-1295 + Ipamorelin as a combination research compound, with no standalone CJC-1295 in either form. The combination appears as the CJC (No DAC) + IPA Blend, a single 10 mg vial with both compounds pre-mixed at a fixed ratio, and as the CJC (No DAC) + IPA Stack.
"CJC" in the product name is the CJC-1295 component, and "IPA" is Ipamorelin, a ghrelin-receptor agonist often paired with the no-DAC form. Kylo's product pages describe the CJC-1295 as modified GRF(1-29) without the albumin-binding Drug Affinity Complex.
Researchers should confirm the CJC-1295 form from that description and the linked documentation, since the generic name alone does not settle it. Composition also needs confirming before any comparison with standalone CJC-1295 from other sources.
CJC-1295 + Ipamorelin: What Researchers Should Verify
A combination research compound needs a few checks before it enters a study. Each check confirms one part of the material: which compounds it contains, how they are combined, and which lot it came from, so the vial and its paperwork describe the same thing.
Compound Identification
Confirm that the product documentation names both CJC-1295 and Ipamorelin. Then check that the CJC-1295 form is stated as "With DAC" or "No DAC."
Product Composition
Review the stated composition, including total content and whether both compounds share one vial. A combination product is its own material and is not equivalent to standalone CJC-1295.
Batch-Level Documentation
Note the lot number on the vial, then review the COA for that lot and confirm it covers the same material.
Why DAC vs No DAC Matters When Comparing Research Materials
The DAC vs. no-DAC distinction shapes how researchers read the literature. The DAC form carries an extra albumin-binding group that changes its molecular mass and, in published studies, gives it a half-life measured in days. The no-DAC form lacks that group.
Before comparing results, researchers should establish which form each study used, because the two names refer to different molecules. The same specificity applies to a combination product, where the CJC-1295 form and the second compound both shape the comparison.
The Research Risks of Ambiguous Peptide Labeling
Ambiguous compound names appear across research peptide catalogs. KMD Analytical describes receiving the wrong DAC variant as "the single most common identity problem" with this compound. When one name covers more than one molecule, comparing products or papers gets harder.
The effects reach several parts of a study:
**Research reproducibility: a 2015 analysis in PLoS Biology estimated that more than 50% of preclinical research is irreproducible. It named biological reagents and reference materials as two of four primary causes.
**Experimental documentation: a methods section that says only "CJC-1295" leaves the form open.
**Literature comparisons: results from one form can look out of line against the other.
**Material verification: a vague label leaves identity to chance.
How Kylo's Catalog Documentation Supports Compound Identification
Kylo presents its CJC-1295 + Ipamorelin product with "No DAC" in the title and a description that names modified GRF(1-29), so the listing itself identifies the form. The Blend listing links to batch-specific certificates in Kylo's public COA library, which lists two independent certificates:
**Freedom Diagnostics: lot SD-260727-1, 99.62% purity, identity confirmed by LC-MS, reported Aug. 22, 2026.
**Vanguard Laboratory: report V260814-13 004, "CJC-1295 no DAC/Ipamorelin," 98.56% purity by HPLC-UV/VIS, reported Aug. 20, 2026.
Both certificates test the blend as a whole, confirming identity and purity at the blend level.
Aligning Product Information With Batch Documentation
Traceability depends on three items matching: the product listing, the lot number printed on the vial, and the certificate for that lot. Kylo matches each certificate to the lot ID on the vial. Together, they let a researcher trace exactly which material a study used.
How Researchers Can Distinguish CJC-1295 Forms Before Comparing Products
Not every product labeled "CJC-1295" is chemically identical, and a quick check before comparing products can prevent a mismatched study. Researchers can work through this neutral checklist for any CJC-1295 listing, from any source, before the material enters a protocol:
1 - Identify whether DAC is specified as "With DAC" or "No DAC."
2 - Check whether the listing or paper references Mod GRF 1-29.
3 - Determine whether the material is standalone CJC-1295 or a combination product.
4 - Review the stated composition, including every compound and the total content.
5 - Match the product to its batch documentation by lot number.
6 - Compare the terminology against the research literature the study builds on.
Kylo Peptides does not provide dosing guidance.
CJC-1295 + Ipamorelin and Research Documentation
Combination products need each component named clearly in the lab record. For this blend, a complete entry lists both compounds, the CJC-1295 form (No DAC, also called Mod GRF 1-29), the stated composition, and the lot number with its certificate of analysis.
Logging the blend under its full name keeps its results separate from studies of either standalone CJC-1295 form.
Accessing Kylo's Updated Product Information
Researchers can find the updated listings in the Kylo Peptides catalog, where the Blend page links to its lot certificates. The public COA library at kylopeptides.com/coa lists each certificate by compound, lot number, purity, and laboratory. Kylo encourages researchers to check the current description and batch documentation before starting laboratory work.
All Kylo Peptides compounds are for laboratory research only and are not for human or veterinary use.
Maintaining Accuracy Across Research Compound Listings
Kylo Peptides says it reviews its research compound listings periodically, focusing on names that can refer to more than one material. According to the company, when a name, form, or certificate record needs clearer wording, it updates the listing and its linked documents together.
The CJC-1295 + Ipamorelin listing is one result of that review. Kylo treats labeling accuracy as part of catalog maintenance, alongside lot certificates from four independent laboratories.
FAQs
Does Kylo Peptides sell standalone CJC-1295?
No. Kylo lists CJC-1295 only in combination with Ipamorelin.
What CJC-1295 product is listed in the Kylo catalog?
CJC-1295 + Ipamorelin, offered as the CJC (No DAC) + IPA Blend and Stack.
Is CJC-1295 with DAC the same as Mod GRF 1-29?
No. Mod GRF 1-29 is CJC-1295 without DAC.
Why does DAC status matter when identifying CJC-1295?
DAC adds albumin binding and a half-life of days in published studies.
How should researchers evaluate a CJC-1295 + Ipamorelin combination product?
Treat it as its own material and confirm both compounds, the CJC-1295 form, and the composition.
Where can researchers verify the product's batch documentation?
In Kylo's COA library at kylopeptides.com/coa, matched to the lot ID on the vial.
About Kylo Peptides
Kylo Peptides, operated by Kylo Labs LLC in Sheridan, Wyoming, supplies research compounds to qualified laboratories and institutions for research use only. Process chemists and QC analysts set up the company in 2021.
Kylo publishes lot certificates in a public COA library, each matched to the lot number printed on the vial, with results from four independent laboratories. Its CJC-1295 + Ipamorelin listing names each compound and the CJC-1295 form in the title. More information is available at kylopeptides.com.
Disclaimers
For Research Use Only. Not for human or veterinary use. The U.S. Food and Drug Administration has not evaluated these statements.
"CJC-1295" covers two different molecules. The DAC form carries an albumin-binding group that extends its half-life to days in published studies. Mod GRF 1-29 omits that group.
Freedom Diagnostics, an ISO/IEC 17025-accredited lab, confirmed the blend's identity by LC-MS at 99.62% purity on Aug. 22, 2026. The certificate is in Kylo's public COA library.
Why CJC-1295 Labeling Requires Precision
The name "CJC-1295" appears in research literature and supplier catalogs for two related compounds: CJC-1295 with DAC and CJC-1295 without DAC, often called Mod GRF 1-29. Published studies describe the two forms with different chemical structures and very different half-lives.
Independent testing lab KMD Analytical notes that vendors sell the no-DAC compound under several names and spellings. Researchers reviewing a specification, paper, COA, or vial should not treat the terms as interchangeable.
Combination products need the same clarity. A CJC-1295 + Ipamorelin listing has to name both compounds and state which CJC-1295 form it carries.
Understanding the Two CJC-1295 Research Forms
Both CJC-1295 research forms are built on modified GRF(1-29), a 29-amino-acid analog of the first 29 residues of growth hormone-releasing hormone (GHRH). They differ by one added group at the end of the chain, which changes albumin binding and persistence.
CJC-1295 With DAC
DAC stands for Drug Affinity Complex, a lysine carrying a maleimidopropionamide group at the end of a tetrasubstituted GRF(1-29). Published studies have described it as binding to serum albumin.
A 2005 rat study detected the compound in plasma beyond 72 hours, and a trial in healthy adults estimated its half-life at 5.8 to 8.1 days.
CJC-1295 Without DAC / Mod GRF 1-29
CJC-1295 No DAC is the same tetrasubstituted GRF(1-29) amide with no DAC attached, often called Mod GRF 1-29 in research papers. Four amino-acid substitutions, at positions 2, 8, 15, and 27, resist breakdown by the enzyme DPP-IV. Without the albumin-binding group, it lacks the extended half-life reported for the DAC form.
Why the Names Should Not Be Used Interchangeably
Similar names make it easy to mix up a paper, a catalog listing, and a vial. A result for one form may not carry over to the other, so exact identification keeps each comparison on one molecule.
Where Kylo's CJC-1295 + Ipamorelin Product Fits
Kylo's catalog includes CJC-1295 + Ipamorelin as a combination research compound, with no standalone CJC-1295 in either form. The combination appears as the CJC (No DAC) + IPA Blend, a single 10 mg vial with both compounds pre-mixed at a fixed ratio, and as the CJC (No DAC) + IPA Stack.
"CJC" in the product name is the CJC-1295 component, and "IPA" is Ipamorelin, a ghrelin-receptor agonist often paired with the no-DAC form. Kylo's product pages describe the CJC-1295 as modified GRF(1-29) without the albumin-binding Drug Affinity Complex.
Researchers should confirm the CJC-1295 form from that description and the linked documentation, since the generic name alone does not settle it. Composition also needs confirming before any comparison with standalone CJC-1295 from other sources.
CJC-1295 + Ipamorelin: What Researchers Should Verify
A combination research compound needs a few checks before it enters a study. Each check confirms one part of the material: which compounds it contains, how they are combined, and which lot it came from, so the vial and its paperwork describe the same thing.
Compound Identification
Confirm that the product documentation names both CJC-1295 and Ipamorelin. Then check that the CJC-1295 form is stated as "With DAC" or "No DAC."
Product Composition
Review the stated composition, including total content and whether both compounds share one vial. A combination product is its own material and is not equivalent to standalone CJC-1295.
Batch-Level Documentation
Note the lot number on the vial, then review the COA for that lot and confirm it covers the same material.
Why DAC vs No DAC Matters When Comparing Research Materials
The DAC vs. no-DAC distinction shapes how researchers read the literature. The DAC form carries an extra albumin-binding group that changes its molecular mass and, in published studies, gives it a half-life measured in days. The no-DAC form lacks that group.
Before comparing results, researchers should establish which form each study used, because the two names refer to different molecules. The same specificity applies to a combination product, where the CJC-1295 form and the second compound both shape the comparison.
The Research Risks of Ambiguous Peptide Labeling
Ambiguous compound names appear across research peptide catalogs. KMD Analytical describes receiving the wrong DAC variant as "the single most common identity problem" with this compound. When one name covers more than one molecule, comparing products or papers gets harder.
The effects reach several parts of a study:
**Research reproducibility: a 2015 analysis in PLoS Biology estimated that more than 50% of preclinical research is irreproducible. It named biological reagents and reference materials as two of four primary causes.
**Experimental documentation: a methods section that says only "CJC-1295" leaves the form open.
**Literature comparisons: results from one form can look out of line against the other.
**Material verification: a vague label leaves identity to chance.
How Kylo's Catalog Documentation Supports Compound Identification
Kylo presents its CJC-1295 + Ipamorelin product with "No DAC" in the title and a description that names modified GRF(1-29), so the listing itself identifies the form. The Blend listing links to batch-specific certificates in Kylo's public COA library, which lists two independent certificates:
**Freedom Diagnostics: lot SD-260727-1, 99.62% purity, identity confirmed by LC-MS, reported Aug. 22, 2026.
**Vanguard Laboratory: report V260814-13 004, "CJC-1295 no DAC/Ipamorelin," 98.56% purity by HPLC-UV/VIS, reported Aug. 20, 2026.
Both certificates test the blend as a whole, confirming identity and purity at the blend level.
Aligning Product Information With Batch Documentation
Traceability depends on three items matching: the product listing, the lot number printed on the vial, and the certificate for that lot. Kylo matches each certificate to the lot ID on the vial. Together, they let a researcher trace exactly which material a study used.
How Researchers Can Distinguish CJC-1295 Forms Before Comparing Products
Not every product labeled "CJC-1295" is chemically identical, and a quick check before comparing products can prevent a mismatched study. Researchers can work through this neutral checklist for any CJC-1295 listing, from any source, before the material enters a protocol:
1 - Identify whether DAC is specified as "With DAC" or "No DAC."
2 - Check whether the listing or paper references Mod GRF 1-29.
3 - Determine whether the material is standalone CJC-1295 or a combination product.
4 - Review the stated composition, including every compound and the total content.
5 - Match the product to its batch documentation by lot number.
6 - Compare the terminology against the research literature the study builds on.
Kylo Peptides does not provide dosing guidance.
CJC-1295 + Ipamorelin and Research Documentation
Combination products need each component named clearly in the lab record. For this blend, a complete entry lists both compounds, the CJC-1295 form (No DAC, also called Mod GRF 1-29), the stated composition, and the lot number with its certificate of analysis.
Logging the blend under its full name keeps its results separate from studies of either standalone CJC-1295 form.
Accessing Kylo's Updated Product Information
Researchers can find the updated listings in the Kylo Peptides catalog, where the Blend page links to its lot certificates. The public COA library at kylopeptides.com/coa lists each certificate by compound, lot number, purity, and laboratory. Kylo encourages researchers to check the current description and batch documentation before starting laboratory work.
All Kylo Peptides compounds are for laboratory research only and are not for human or veterinary use.
Maintaining Accuracy Across Research Compound Listings
Kylo Peptides says it reviews its research compound listings periodically, focusing on names that can refer to more than one material. According to the company, when a name, form, or certificate record needs clearer wording, it updates the listing and its linked documents together.
The CJC-1295 + Ipamorelin listing is one result of that review. Kylo treats labeling accuracy as part of catalog maintenance, alongside lot certificates from four independent laboratories.
FAQs
Does Kylo Peptides sell standalone CJC-1295?
No. Kylo lists CJC-1295 only in combination with Ipamorelin.
What CJC-1295 product is listed in the Kylo catalog?
CJC-1295 + Ipamorelin, offered as the CJC (No DAC) + IPA Blend and Stack.
Is CJC-1295 with DAC the same as Mod GRF 1-29?
No. Mod GRF 1-29 is CJC-1295 without DAC.
Why does DAC status matter when identifying CJC-1295?
DAC adds albumin binding and a half-life of days in published studies.
How should researchers evaluate a CJC-1295 + Ipamorelin combination product?
Treat it as its own material and confirm both compounds, the CJC-1295 form, and the composition.
Where can researchers verify the product's batch documentation?
In Kylo's COA library at kylopeptides.com/coa, matched to the lot ID on the vial.
About Kylo Peptides
Kylo Peptides, operated by Kylo Labs LLC in Sheridan, Wyoming, supplies research compounds to qualified laboratories and institutions for research use only. Process chemists and QC analysts set up the company in 2021.
Kylo publishes lot certificates in a public COA library, each matched to the lot number printed on the vial, with results from four independent laboratories. Its CJC-1295 + Ipamorelin listing names each compound and the CJC-1295 form in the title. More information is available at kylopeptides.com.
Disclaimers
For Research Use Only. Not for human or veterinary use. The U.S. Food and Drug Administration has not evaluated these statements.
Contact
Kylo Research Labs LLC
Courtney Brooks
+1 350 252 3314
kylopeptides.com/
Address: 30 N Gould St, Ste R, Sheridan, WY 82801
Courtney Brooks
+1 350 252 3314
kylopeptides.com/
Address: 30 N Gould St, Ste R, Sheridan, WY 82801
Contact
Categories